Skip to Content

'
Dejka M. (Steinert) Araujo, M.D.

Present Title & Affiliation

Primary Appointment

Associate Professor, Department of Sarcoma Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Office Address

The University of Texas MD Anderson Cancer Center
P.O. Box 301402, Unit 450
Unit Number: 450
Houston, TX 77230-1402

Education & Training

Degree-Granting Education

1999 University of Arkansas for Medical Sciences, Little Rock, AR, MD, Medical Sciences
1995 Notre Dame, Notre Dame, IN, BA, Theology

Postgraduate Training

2002-2005 Clinical Fellowship, The University of Texas MD Anderson Cancer Center, Houston, TX
2000-2002 Clinical Residency, University of Alabama, Birmingham, AL
1999-2000 Clinical Internship, University of Alabama, Birmingham, AL

Board Certifications

11/2007 Medical Oncology
8/2002 Internal Medicine

Experience/Service

Academic Appointments

Associate Faculty Member, The University of Texas Graduate School of Biomedical Sciences, Houston, TX, 10/2009-present
Assistant Professor, Department of Sarcoma Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 7/2005-8/2011

Institutional Committee Activities

Associate Member, M.D. Anderson Cancer Center Institutional Review Board I, 10/2008-8/2011
Chair, M.D. Anderson Cancer Center Clinical Research Committee II, 9/2008-8/2011
Member, M.D. Anderson Cancer Center Clinical Affairs Committee of the Faculty Senate, 11/2006-present
Member, M.D. Anderson Cancer Center Faculty Senate, 9/2006-5/2009

Selected Publications

Peer-Reviewed Original Research Articles

1. Katz D, Boonsirikamchai P, Choi H, Lazar AJ, Wang WW, Xiao L, Park MS, Ravi V, Benjamin RS, Araujo DM. Efficacy of first-line doxorubicin and ifosfamide in myxoid liposarcoma. Clinical Sarcoma Research 2(1):2, 1/2012.
2. Park MS, Patel SR, Ludwig JA, Trent JC, Conrad CA, Lazar AJ, Wang WL, Boonsirikamchai P, Choi H, Wang X, Benjamin RS, Araujo DM. Activity of temozolomide and bevacizumab in the treatment of locally advanced, recurrent, and metastatic hemangiopericytoma and malignant solitary fibrous tumor. Cancer, 11/2011. PMID: 21480200.
3. Shinder R, Jackson TL, Araujo D, Prieto VG, Guadagnolo BA, Esmaeli B. Preoperative Radiation Therapy in the Management of Recurrent Orbital Hemangiopericytoma. Ophthal Plast Reconstr Surg, 1/2011. PMID: 21242853.
4. Pandurengan RK, Dumont AG, Araujo DM, Ludwig JA, Ravi V, Patel S, Garber J, Benjamin RS, Strom SS, Trent JC. Survival of Patients with Multiple Primary Malignancies: A Study of 783 Patients with Gastrointestinal Stromal Tumor. Annals of Oncology 21(10):2107-11, 10/2010. PMID: 20348145.
5. Vadhan-Raj S, Trent J, Patel S, Zhou X, Johnson MM, Araujo D, Ludwig J, O'Roark S, Gillenwater AM, Bueso-Ramos C, El-Naggar AK, Benjamin RS. Single-Dose Palifermin Prevents Severe Oral Mucositis During Multicycle Chemotherapy in Patients with Cancer. Annals of Internal Medicine 153(6):358-367, 9/2010.
6. Jonathan C. Trent, MD, PhD, Shalin S. Patel, Jianhu Zhang, PhD, Dejka Araujo, MD, Juan-Carlos Plana, MD, Daniel J. Lenihan, MD, Dominic Fan, PhD, Shreyaskumar R. Patel, MD, Robert S. Benjamin, MD, and Aarif Y. Khakoo, MD. Rare Incidence of Congestive Heart Failure in Gastrointestinal Stromal Tumor and Other Sarcoma Patients Receiving Imatinib Mesylate. Cancer 116(1):184-192, 1/2010. PMID: 19885836.
7. Wang WL, Mayordomo E, Czerniak BA, Abruzzo LV, Cin PD, Araujo DM, Lev DC, López-Terrada D, Lazar AJ. Fluorescence in situ hybridization is a useful ancillary diagnostic tool for extraskeletal myxoid chondrosarcoma. Mod Pathol 21(11):1303-10, 11/2008. PMID: 18587326.
8. Shome D, Trent J, Espandar L, Hatef E, Araujo DM, Song CD, Kim SK, Esmaeli B. Ulcerative keratitis in gastrointestinal stromal tumor patients treated with perifosine. Ophthalmology 115(3):483-7, 3/2008. PMID: 18201764.
9. McAuliffe JC, Lazar AJ, Yang D, Steinert DM, Qiao W, Thall PF, Raymond AK, Benjamin RS, Trent JC. Association of intratumoral vascular endothelial growth factor expression and clinical outcome for patients with gastrointestinal stromal tumors treated with imatinib mesylate. Clin Cancer Res 13(22 Pt 1):6727-34, 11/2007. PMID: 18006774.
10. Armistead PM, Salganick J, Roh JS, Steinert DM, Patel S, Munsell M, El-Naggar AK, Benjamin RS, Zhang W, Trent JC. Expression of receptor tyrosine kinases and apoptotic molecules in rhabdomyosarcoma: correlation with overall survival in 105 patients. Cancer 110(10):2293-303, 11/2007. PMID: 17896786.
11. Chirieac LR, Trent JC, Steinert DM, Choi H, Yang Y, Zhang J, Patel SR, Benjamin RS, Raymond AK. Correlation of immunophenotype with progression-free survival in patients with gastrointestinal stromal tumors treated with imatinib mesylate. Cancer 107(9):2237-44, 11/2006. PMID: 16998931.
12. Steinert DM, Oyarzo M, Wang X, Choi H, Thall PF, Medeiros LJ, Raymond AK, Benjamin RS, Zhang W, Trent JC. Expression of Bcl-2 in gastrointestinal stromal tumors: correlation with progression-free survival in 81 patients treated with imatinib mesylate. Cancer 106(7):1617-23, 4/2006. PMID: 16518826.
13. Steinert DM, McAuliffe JC, Trent JC. Imatinib mesylate in the treatment of gastrointestinal stromal tumour. Expert Opin Pharmacother 6(1):105-13, 1/2005. PMID: 15709888.
14. D'Amato G, Steinert DM, McAuliffe JC, Trent JC. Update on the biology and therapy of gastrointestinal stromal tumors. Cancer Control 12(1):44-56, 1/2005. PMID: 15668652.

Invited Articles

1. Park MS, Ravi V, Araujo DM. Inhibiting the VEGF-VEGFR Pathway in Angiosarcoma, Epithelioid Hemangioendothelioma, and Hemangiopericytoma/Solitary Fibrous Tumor. Current Opinion in Oncology 22(4):351-355, 7/2010.
2. Park MS, Araujo DM. New insights into the hemangiopericytoma/solitary fibrous tumor spectrum of tumors. Current Opinion in Oncology 21(4):327-31, 7/2009. PMID: 19444101.
3. Steinert DM, Patel SR. Recent studies in novel therapy for metastatic sarcomas. Hematol Oncol Clin North Am 19(3):573-90, viii, 6/2005. PMID: 15939198.
4. Steinert DM, Blakely LJ, Salganick J, Trent JC. Molecular targets in therapy for human soft-tissue and bone sarcomas. Curr Oncol Rep 5(4):295-303, 7/2003. PMID: 12781071.

Abstracts

1. Hensley ML, Wathen K, Maki RG, Araujo DM, Sutton GP, Priebat DA, George S, Baker LH. 3-year follow-up of SARC005: Adjuvant treatment og high risk primary uterine leiomyosarcoma with gemcitabine/docetaxel (GT), followed by doxorubicin (D). CTOS(Poster #78):38, 10/2011.
2. Trent JC, Salganick JA, Thall PF, Patel SR, Araujo DM, Benjamin RS. Efficacy and safety of low-dose protracted irinotecan in patients with advanced sarcomas: results from a phase II study. CTOS - Oral Presentation:90, 10/2011.
3. Demicco E, Park M, Araujo D, Bassett R, Lazar AJ, Wang WL,. Solitary fibrous tumor/hemangiopericytoma: clinicopathologic predictors of outcome. CTOS(Poster # 205):55, 10/2011.
4. Dumont SN, Trent JC, Patel S, Araujo DM, Dumont AG, Benjamin RS. A phase II study of low-dose protracted irinotecan in patients with advanced sarcomas. ASCO (#10064), 6/2011.
5. Gao J, McAuliffe JC, Lazar AJF, Wang W, Choi H, Hunt K, Araujo DM, Pollock RE, Benjamin RS, Trent JC. Mechanism of early radiographic response to imatinib in GIST. ASCO (#10049), 6/2011.
6. Park MS, Patel S, Ravi V, Conley AP, Trent JC, Lazar AJF, Lev D, Wang X, Benjamin RS, Araujo DM. The role of chemotherapy in advanced hemangiopericyoma/solitary fibrous tumor. ASCO (#10097), 6/2011.
7. Ravi V, Yang J, Araujo DM, Park MS, Benjamin RS, Zhang W, Trent JC, Patel S. The role of E-cadherin expression in response and outcome in patients with leiomyosarcoma treated with chemotherapy. ASCO (#10096), 6/2011.
8. Hensley ML, Wathen K, Maki RG, Araujo DM, Sutton G, Priebat DA, George S, Baker LH,. Adjuvant Treatment of High-Risk Primary Uterine Leiomyosarcoma with Gemcitabine/Docetaxel (GT), Followed by Doxorubicin (D): Results of Phase II Multicenter Trial SARC005. ASCO (#10021), 2010.
9. Dumont SN, Araujo DM, Dumont AG, Conley AP, Reynoso DG, Raymond K, Munsel MF, Patel S, Benjamin RS, Trent JC. Adult Rhabdomyosarcoma: 239 Patients Followed at MD Anderson Cancer Center. CTOS Oral Presentation (#899871), 2010.
10. Katz D, Boonsirikamchai P, Benjamin RS, Patel S, Ludwig JA, Trent JC, Xiao L, Ravi V, Choi H, Araujo DM. Efficacy of Neoadjuvant Doxorubicin and Ifosfamide (AI) in Myxoid/Round Cell Liposarcoma (MRCL): The M.D. Anderson Cancer Center Experience (MDACC). ASCO (#10080), 2010.
11. Wang WL, Katz D, Araujo DM, Ravi V, Ludwig JA, Trent JC, Patel SR, Lewis VO, Lin P, Pollock RE, Guadagnolo A, Zagars G, Benjamin RS, Madewell JE, Lazar AJ. Extensive fatty maturation can be seen in myxoid liposarcomas treated with neoadjuvant doxorubicin and ifosamide and pre-operative radiation therapy. CTOS, 2010.
12. Ravi V, Wang W, Araujo DM, Ludwig JA, Luke RJ, Lewis VO, Trent JC, Benjamin RS, Patel S. Imatinib in the Treatment of Tenosynovial Giant-Cell Tumor and Pigmented Villonodular Synovitis. ASCO (#10011), 2010.
13. Park MS, Patel S, Trent JC, Wang W, Conley AP, Benjamin RS, Araujo DM. Multidisciplinary Management of Patients with Primary Pulmonary Artery Sarcoma (PPAS). ASCO (#e20501), 2010.
14. Park MS, Patel SR, Trent JC, Wang WL, Conley AP, Benjamin RS, Araujo DM. Multidisciplinary management of patients with primary pulmonary artery sarcoma (PPAS). CTOS (#899148), 2010.
15. A.P. Conley, D. Araujo, J. Ludwig, V. Ravi, B.L. Samuels, H. Choi, P.F. Thall, S. Patel, R. Benjamin, J. Trent,. A randomized phase II study of perifosine (P) plus imatinib for patients with imatinib-resistant gastrointestinal stromal tumor (GIST). ASCO (#10563), 2009.
16. S. Vadhan-Raj, J. Trent, D.M. Araujo, S. Patel, X. Zhou, R.S. Benjamin. Evaluation of AMG 531 in chemotherapy-induced thrombocytopenia (CIT): Results of a phase I/II study. ASCO (#e20616), 2009.
17. Park MS, Lazar AJ, Trent JC, Conrad CA, Ludwig JA, Wang WL, Boonsirikamachi P, Choi H, Patel SR, Benjamin RS, Araujo DM. Combination therapy with temozolamide and bevacizumab (TMS/BV) in he treatment of hemangiopericytoma/solitary fibrous tumor (HPC/SFT): An updated analysis. CTOS Oral Presentation (##35064), 2008.
18. Park MS, Patel SR, Ludwig JA, Trent JC, Conrad CA, Lazar AJ, Choi H, Benjamin RS, Araujo DM. Combination therapy with temozolamide and bevacizumab in the treatment of hemangiopericytoma/malignant solitary fibrous tumor. ASCO (#10512), 2008.
19. Vadhan-Raj S, Trent JC, Patel SR, Araujo DM, Ludwig JA, Bailey D, Zhou X, Gillenwater A, El-Naggar A, Benjamin RS. Randomized, double-blind, placebo-controlled study of palifermin for the prevention of mucositis in patients receiving doxorubicin-based chemotherapy. ASCO (#9547), 2008.
20. Steinert D, Henderson C, Chawla S, Staddon A, Schuetze S, Ryan C. A phase II trial of perifosine in patients with chemoinsensitive sarcomas: Preliminary results A Sarcoma for Reseach through Collaboration (SARC) Study. Connective Tissue Oncology Society (#860), 2007.
21. Lenihan DJ, Massey MR, Baysinger K, Steinert D, Fayad L, Yusuf SW, Chiu A, Durand J, Yeh ET. Early detection of cardiotoxicity during chemotherapy using biomarkers. ASCO (#19521), 2007.
22. McAuliffe JC, Lazar A, Steinert D, Patel S, Benjamin R, Trent. Kit-stem cell factor (kit ligand) axis in GIST treated with imatinib. ASCO (#10046), 2007.
23. Khakoo AY, Steinert DM, Patel SR, Plana JC, Ludwig J, Benjamin RS, Trent JC. Rare incidence of congestive heart failure (CHF) in gastrointestinal stromal tumors (GIST) and other sarcoma patients (pts) receiving imatinib mesylate (IM) therapy. ASCO (#10026), 2007.

Book Chapters

1. Steinert DM, Trent JC:. Gastrointestinal stromal tumors. In: Ajani JA, Curley SA, Janjan NA, Lynch PM Gastrointestinal Cancer. 3, M.D. Anderson Cancer Care Series. Ed(s) Buzdar AU, Freedman RS. Springer Science + Business Media, Inc: New York, 2005.

Last updated: 7/3/2014